View in EDS HTML Full Text PDF Full Text

Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL.

Saved in:
Bibliographic Details
Title: Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL.
Authors: Arseni L; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Sigismondo G; Division of Proteomics of Stem Cells and Cancer, German Cancer Research Center, Heidelberg, Germany.; Heidelberg University, Medical Faculty, Heidelberg, Germany., Yazdanparast H; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Hermansen JU; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; K. G. Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Mack N; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Ohl S; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Kalter V; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Iskar M; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Kalxdorf M; Cellzome, a GSK Company, Heidelberg, Germany., Friedel D; Division of Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany., Rettel M; EMBL, Proteomics Core Facility, Heidelberg, Germany., Paul Y; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Ringshausen I; Department of Haematology, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, United Kingdom., Eldering E; Department of Experimental Immunology, Cancer Center Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands., Dubois J; Department of Hematology, Cancer Center Amsterdam, Amsterdam Institute for Infection and Immunity, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands., Kater AP; Department of Hematology, Cancer Center Amsterdam, Amsterdam Institute for Infection and Immunity, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands., Zapatka M; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Roessner PM; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Tausch E; Division of CLL, Department of Internal Medicine III, Ulm University, Ulm, Germany., Stilgenbauer S; Division of CLL, Department of Internal Medicine III, Ulm University, Ulm, Germany., Dietrich S; Heidelberg University, Department of Hematology, Heidelberg, Germany.; Düsseldorf University, Department of Hematology, Düsseldorf, Germany., Savitski MM; EMBL, Proteomics Core Facility, Heidelberg, Germany.; European Molecular Biology Laboratory (EMBL), Genome Biology Unit, Heidelberg, Germany., Skånland SS; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; K. G. Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Krijgsveld J; Division of Proteomics of Stem Cells and Cancer, German Cancer Research Center, Heidelberg, Germany.; Heidelberg University, Medical Faculty, Heidelberg, Germany., Lichter P; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Seiffert M; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany. m.seiffert@dkfz.de.
Source: Nature communications [Nat Commun] 2025 Jan 26; Vol. 16 (1), pp. 1041. Date of Electronic Publication: 2025 Jan 26.
Publication Type: Journal Article
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39863584
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Arseni+L%22">Arseni L</searchLink>; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Sigismondo+G%22">Sigismondo G</searchLink>; Division of Proteomics of Stem Cells and Cancer, German Cancer Research Center, Heidelberg, Germany.; Heidelberg University, Medical Faculty, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Yazdanparast+H%22">Yazdanparast H</searchLink>; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Hermansen+JU%22">Hermansen JU</searchLink>; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; K. G. Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Mack+N%22">Mack N</searchLink>; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Ohl+S%22">Ohl S</searchLink>; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Kalter+V%22">Kalter V</searchLink>; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Iskar+M%22">Iskar M</searchLink>; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Kalxdorf+M%22">Kalxdorf M</searchLink>; Cellzome, a GSK Company, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Friedel+D%22">Friedel D</searchLink>; Division of Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Rettel+M%22">Rettel M</searchLink>; EMBL, Proteomics Core Facility, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Paul+Y%22">Paul Y</searchLink>; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Ringshausen+I%22">Ringshausen I</searchLink>; Department of Haematology, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Eldering+E%22">Eldering E</searchLink>; Department of Experimental Immunology, Cancer Center Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Dubois+J%22">Dubois J</searchLink>; Department of Hematology, Cancer Center Amsterdam, Amsterdam Institute for Infection and Immunity, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Kater+AP%22">Kater AP</searchLink>; Department of Hematology, Cancer Center Amsterdam, Amsterdam Institute for Infection and Immunity, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Zapatka+M%22">Zapatka M</searchLink>; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Roessner+PM%22">Roessner PM</searchLink>; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Tausch+E%22">Tausch E</searchLink>; Division of CLL, Department of Internal Medicine III, Ulm University, Ulm, Germany.<br /><searchLink fieldCode="AU" term="%22Stilgenbauer+S%22">Stilgenbauer S</searchLink>; Division of CLL, Department of Internal Medicine III, Ulm University, Ulm, Germany.<br /><searchLink fieldCode="AU" term="%22Dietrich+S%22">Dietrich S</searchLink>; Heidelberg University, Department of Hematology, Heidelberg, Germany.; Düsseldorf University, Department of Hematology, Düsseldorf, Germany.<br /><searchLink fieldCode="AU" term="%22Savitski+MM%22">Savitski MM</searchLink>; EMBL, Proteomics Core Facility, Heidelberg, Germany.; European Molecular Biology Laboratory (EMBL), Genome Biology Unit, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Skånland+SS%22">Skånland SS</searchLink>; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; K. G. Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Krijgsveld+J%22">Krijgsveld J</searchLink>; Division of Proteomics of Stem Cells and Cancer, German Cancer Research Center, Heidelberg, Germany.; Heidelberg University, Medical Faculty, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Lichter+P%22">Lichter P</searchLink>; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Seiffert+M%22">Seiffert M</searchLink>; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany. m.seiffert@dkfz.de.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101528555%22">Nature communications</searchLink> [Nat Commun] 2025 Jan 26; Vol. 16 (1), pp. 1041. <i>Date of Electronic Publication: </i>2025 Jan 26.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101528555 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2041-1723 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220411723%22">20411723 </searchLink><i>NLM ISO Abbreviation: </i>Nat Commun <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39863584
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41467-025-56318-7
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1041
    Titles:
      – TitleFull: Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Arseni L
      – PersonEntity:
          Name:
            NameFull: Sigismondo G
      – PersonEntity:
          Name:
            NameFull: Yazdanparast H
      – PersonEntity:
          Name:
            NameFull: Hermansen JU
      – PersonEntity:
          Name:
            NameFull: Mack N
      – PersonEntity:
          Name:
            NameFull: Ohl S
      – PersonEntity:
          Name:
            NameFull: Kalter V
      – PersonEntity:
          Name:
            NameFull: Iskar M
      – PersonEntity:
          Name:
            NameFull: Kalxdorf M
      – PersonEntity:
          Name:
            NameFull: Friedel D
      – PersonEntity:
          Name:
            NameFull: Rettel M
      – PersonEntity:
          Name:
            NameFull: Paul Y
      – PersonEntity:
          Name:
            NameFull: Ringshausen I
      – PersonEntity:
          Name:
            NameFull: Eldering E
      – PersonEntity:
          Name:
            NameFull: Dubois J
      – PersonEntity:
          Name:
            NameFull: Kater AP
      – PersonEntity:
          Name:
            NameFull: Zapatka M
      – PersonEntity:
          Name:
            NameFull: Roessner PM
      – PersonEntity:
          Name:
            NameFull: Tausch E
      – PersonEntity:
          Name:
            NameFull: Stilgenbauer S
      – PersonEntity:
          Name:
            NameFull: Dietrich S
      – PersonEntity:
          Name:
            NameFull: Savitski MM
      – PersonEntity:
          Name:
            NameFull: Skånland SS
      – PersonEntity:
          Name:
            NameFull: Krijgsveld J
      – PersonEntity:
          Name:
            NameFull: Lichter P
      – PersonEntity:
          Name:
            NameFull: Seiffert M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 26
              M: 01
              Text: 2025 Jan 26
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2041-1723
          Numbering:
            – Type: volume
              Value: 16
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Nature communications
              Type: main
ResultId 1